nodes	percent_of_prediction	percent_of_DWPC	metapath
Tretinoin—peripheral nervous system neoplasm—muscle cancer	0.576	1	CtDrD
Tretinoin—NR0B1—Vincristine—muscle cancer	0.183	0.647	CbGbCtD
Tretinoin—CYP1A1—Dacarbazine—muscle cancer	0.03	0.106	CbGbCtD
Tretinoin—CYP3A7—Vincristine—muscle cancer	0.0128	0.0453	CbGbCtD
Tretinoin—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0128	0.0453	CbGbCtD
Tretinoin—CYP3A5—Vincristine—muscle cancer	0.00963	0.034	CbGbCtD
Tretinoin—CYP3A5—Etoposide—muscle cancer	0.00882	0.0312	CbGbCtD
Tretinoin—CYP2C8—Etoposide—muscle cancer	0.00848	0.03	CbGbCtD
Tretinoin—CYP2B6—Doxorubicin—muscle cancer	0.00764	0.027	CbGbCtD
Tretinoin—CYP3A4—Vincristine—muscle cancer	0.00375	0.0133	CbGbCtD
Tretinoin—CYP3A4—Etoposide—muscle cancer	0.00344	0.0122	CbGbCtD
Tretinoin—GPRC5A—renal system—muscle cancer	0.00257	0.061	CbGeAlD
Tretinoin—CYP3A4—Doxorubicin—muscle cancer	0.00235	0.00829	CbGbCtD
Tretinoin—CRABP2—Pyruvate metabolism and Citric Acid (TCA) cycle—FH—muscle cancer	0.00163	0.088	CbGpPWpGaD
Tretinoin—CRABP1—Pyruvate metabolism and Citric Acid (TCA) cycle—FH—muscle cancer	0.00163	0.088	CbGpPWpGaD
Tretinoin—ALDH1A2—embryo—muscle cancer	0.00132	0.0313	CbGeAlD
Tretinoin—CRABP1—embryo—muscle cancer	0.00127	0.0302	CbGeAlD
Tretinoin—RARRES1—cardiac atrium—muscle cancer	0.00117	0.0276	CbGeAlD
Tretinoin—CRABP2—embryo—muscle cancer	0.00115	0.0273	CbGeAlD
Tretinoin—RARRES1—tendon—muscle cancer	0.00102	0.0241	CbGeAlD
Tretinoin—ALDH1A2—renal system—muscle cancer	0.000998	0.0237	CbGeAlD
Tretinoin—CYP4A11—renal system—muscle cancer	0.000963	0.0228	CbGeAlD
Tretinoin—ALDH1A1—embryo—muscle cancer	0.000959	0.0227	CbGeAlD
Tretinoin—RARRES1—vagina—muscle cancer	0.000942	0.0223	CbGeAlD
Tretinoin—CRABP2—smooth muscle tissue—muscle cancer	0.000905	0.0215	CbGeAlD
Tretinoin—ALDH1A1—Teniposide—Etoposide—muscle cancer	0.000884	0.315	CbGdCrCtD
Tretinoin—ALDH1A1—Podofilox—Etoposide—muscle cancer	0.000884	0.315	CbGdCrCtD
Tretinoin—RXRA—renal system—muscle cancer	0.000867	0.0206	CbGeAlD
Tretinoin—RARRES1—testis—muscle cancer	0.000841	0.0199	CbGeAlD
Tretinoin—ALDH1A1—smooth muscle tissue—muscle cancer	0.000754	0.0179	CbGeAlD
Tretinoin—CRABP1—tendon—muscle cancer	0.000752	0.0178	CbGeAlD
Tretinoin—ALDH1A1—renal system—muscle cancer	0.000726	0.0172	CbGeAlD
Tretinoin—NR0B1—testis—muscle cancer	0.000724	0.0172	CbGeAlD
Tretinoin—ALDH1A2—vagina—muscle cancer	0.000723	0.0171	CbGeAlD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.00071	0.0383	CbGpPWpGaD
Tretinoin—CYP4A11—vagina—muscle cancer	0.000698	0.0165	CbGeAlD
Tretinoin—CRABP1—vagina—muscle cancer	0.000698	0.0165	CbGeAlD
Tretinoin—CRABP2—tendon—muscle cancer	0.00068	0.0161	CbGeAlD
Tretinoin—ALDH1A2—head—muscle cancer	0.000668	0.0158	CbGeAlD
Tretinoin—ALDH1A1—cardiac atrium—muscle cancer	0.00065	0.0154	CbGeAlD
Tretinoin—ALDH1A2—testis—muscle cancer	0.000645	0.0153	CbGeAlD
Tretinoin—CRABP1—head—muscle cancer	0.000644	0.0153	CbGeAlD
Tretinoin—RXRB—cardiac atrium—muscle cancer	0.000641	0.0152	CbGeAlD
Tretinoin—CRABP2—The citric acid (TCA) cycle and respiratory electron transport—FH—muscle cancer	0.000633	0.0341	CbGpPWpGaD
Tretinoin—CRABP1—The citric acid (TCA) cycle and respiratory electron transport—FH—muscle cancer	0.000633	0.0341	CbGpPWpGaD
Tretinoin—CRABP2—vagina—muscle cancer	0.000631	0.015	CbGeAlD
Tretinoin—CRABP1—testis—muscle cancer	0.000622	0.0148	CbGeAlD
Tretinoin—ALDH1A1—Vinblastine—Vincristine—muscle cancer	0.000608	0.217	CbGdCrCtD
Tretinoin—RARB—tendon—muscle cancer	0.000608	0.0144	CbGeAlD
Tretinoin—RARA—renal system—muscle cancer	0.000597	0.0142	CbGeAlD
Tretinoin—RXRG—tendon—muscle cancer	0.000594	0.0141	CbGeAlD
Tretinoin—CRABP2—head—muscle cancer	0.000583	0.0138	CbGeAlD
Tretinoin—RXRA—head—muscle cancer	0.00058	0.0138	CbGeAlD
Tretinoin—ALDH1A1—tendon—muscle cancer	0.000566	0.0134	CbGeAlD
Tretinoin—RARB—vagina—muscle cancer	0.000564	0.0134	CbGeAlD
Tretinoin—CRABP2—testis—muscle cancer	0.000563	0.0133	CbGeAlD
Tretinoin—RXRB—tendon—muscle cancer	0.000559	0.0132	CbGeAlD
Tretinoin—ALDH1A1—bone marrow—muscle cancer	0.000549	0.013	CbGeAlD
Tretinoin—ALDH1A2—Tryptophan metabolism—MDM2—muscle cancer	0.000545	0.0294	CbGpPWpGaD
Tretinoin—ALDH1A1—vagina—muscle cancer	0.000526	0.0125	CbGeAlD
Tretinoin—RARB—head—muscle cancer	0.000521	0.0124	CbGeAlD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000519	0.028	CbGpPWpGaD
Tretinoin—RXRB—vagina—muscle cancer	0.000518	0.0123	CbGeAlD
Tretinoin—RXRG—head—muscle cancer	0.000509	0.0121	CbGeAlD
Tretinoin—RARG—tendon—muscle cancer	0.000496	0.0118	CbGeAlD
Tretinoin—RXRA—Pyruvate metabolism and Citric Acid (TCA) cycle—FH—muscle cancer	0.000494	0.0266	CbGpPWpGaD
Tretinoin—RXRG—testis—muscle cancer	0.000492	0.0117	CbGeAlD
Tretinoin—ALDH1A1—head—muscle cancer	0.000486	0.0115	CbGeAlD
Tretinoin—RXRB—head—muscle cancer	0.000479	0.0114	CbGeAlD
Tretinoin—ALDH1A1—testis—muscle cancer	0.000469	0.0111	CbGeAlD
Tretinoin—RARA—tendon—muscle cancer	0.000466	0.0111	CbGeAlD
Tretinoin—RXRB—testis—muscle cancer	0.000463	0.011	CbGeAlD
Tretinoin—CYP2C18—vagina—muscle cancer	0.000462	0.011	CbGeAlD
Tretinoin—RARG—vagina—muscle cancer	0.00046	0.0109	CbGeAlD
Tretinoin—RARA—bone marrow—muscle cancer	0.000452	0.0107	CbGeAlD
Tretinoin—ALDH1A1—Idarubicin—Doxorubicin—muscle cancer	0.000427	0.152	CbGdCrCtD
Tretinoin—RARG—head—muscle cancer	0.000425	0.0101	CbGeAlD
Tretinoin—RARG—testis—muscle cancer	0.000411	0.00974	CbGeAlD
Tretinoin—RARA—head—muscle cancer	0.0004	0.00948	CbGeAlD
Tretinoin—RARA—testis—muscle cancer	0.000386	0.00916	CbGeAlD
Tretinoin—NR0B1—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.000372	0.0201	CbGpPWpGaD
Tretinoin—CYP2A6—vagina—muscle cancer	0.000305	0.00724	CbGeAlD
Tretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000304	0.0164	CbGpPWpGaD
Tretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000304	0.0164	CbGpPWpGaD
Tretinoin—ALDH1A1—Tryptophan metabolism—MDM2—muscle cancer	0.000299	0.0161	CbGpPWpGaD
Tretinoin—RXRG—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.000274	0.0148	CbGpPWpGaD
Tretinoin—RXRA—Transcription factor regulation in adipogenesis—FOXO1—muscle cancer	0.000272	0.0146	CbGpPWpGaD
Tretinoin—RXRB—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.000258	0.0139	CbGpPWpGaD
Tretinoin—CYP4A11—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000254	0.0137	CbGpPWpGaD
Tretinoin—CYP2C8—renal system—muscle cancer	0.000237	0.00561	CbGeAlD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.00023	0.0124	CbGpPWpGaD
Tretinoin—NR0B1—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.000223	0.012	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000222	0.012	CbGpPWpGaD
Tretinoin—CYP1A1—renal system—muscle cancer	0.000218	0.00518	CbGeAlD
Tretinoin—CYP3A5—renal system—muscle cancer	0.000214	0.00507	CbGeAlD
Tretinoin—CYP2B6—renal system—muscle cancer	0.000212	0.00503	CbGeAlD
Tretinoin—RXRG—Adipogenesis—HMGA1—muscle cancer	0.000202	0.0109	CbGpPWpGaD
Tretinoin—RXRA—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000201	0.0109	CbGpPWpGaD
Tretinoin—CYP1A1—cardiac atrium—muscle cancer	0.000196	0.00464	CbGeAlD
Tretinoin—RXRA—The citric acid (TCA) cycle and respiratory electron transport—FH—muscle cancer	0.000192	0.0103	CbGpPWpGaD
Tretinoin—RARA—Adipogenesis—HMGA1—muscle cancer	0.00019	0.0102	CbGpPWpGaD
Tretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—MED12—muscle cancer	0.000182	0.0098	CbGpPWpGaD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000179	0.00964	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000175	0.00942	CbGpPWpGaD
Tretinoin—CYP4A11—PPARA activates gene expression—MED12—muscle cancer	0.000172	0.00929	CbGpPWpGaD
Tretinoin—CYP2C8—vagina—muscle cancer	0.000171	0.00407	CbGeAlD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000171	0.00924	CbGpPWpGaD
Tretinoin—CYP4A11—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	0.000169	0.00909	CbGpPWpGaD
Tretinoin—RXRG—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.000165	0.00888	CbGpPWpGaD
Tretinoin—CYP3A4—renal system—muscle cancer	0.00016	0.0038	CbGeAlD
Tretinoin—CYP1A1—vagina—muscle cancer	0.000158	0.00375	CbGeAlD
Tretinoin—RXRB—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.000155	0.00835	CbGpPWpGaD
Tretinoin—CYP3A5—vagina—muscle cancer	0.000155	0.00367	CbGeAlD
Tretinoin—CYP2B6—vagina—muscle cancer	0.000154	0.00365	CbGeAlD
Tretinoin—CYP2C8—testis—muscle cancer	0.000153	0.00363	CbGeAlD
Tretinoin—CYP1A1—head—muscle cancer	0.000146	0.00347	CbGeAlD
Tretinoin—CYP2B6—head—muscle cancer	0.000142	0.00337	CbGeAlD
Tretinoin—CYP2B6—testis—muscle cancer	0.000137	0.00325	CbGeAlD
Tretinoin—RXRA—PPARA activates gene expression—MED12—muscle cancer	0.000137	0.00736	CbGpPWpGaD
Tretinoin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—muscle cancer	0.000136	0.00734	CbGpPWpGaD
Tretinoin—CYP2A6—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000135	0.00729	CbGpPWpGaD
Tretinoin—RXRA—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.000134	0.00725	CbGpPWpGaD
Tretinoin—RXRG—Adipogenesis—FOXO1—muscle cancer	0.000134	0.00722	CbGpPWpGaD
Tretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	0.000134	0.00721	CbGpPWpGaD
Tretinoin—GPRC5A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000132	0.00712	CbGpPWpGaD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000131	0.00705	CbGpPWpGaD
Tretinoin—RARA—Adipogenesis—FOXO1—muscle cancer	0.000126	0.00679	CbGpPWpGaD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000125	0.00675	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000121	0.00653	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000121	0.00653	CbGpPWpGaD
Tretinoin—NR0B1—Generic Transcription Pathway—MED12—muscle cancer	0.000121	0.00651	CbGpPWpGaD
Tretinoin—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	0.000116	0.00626	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MYF6—muscle cancer	0.000113	0.00608	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MYF5—muscle cancer	0.000113	0.00608	CbGpPWpGaD
Tretinoin—CYP2B6—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000109	0.00588	CbGpPWpGaD
Tretinoin—CYP1A1—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000109	0.00588	CbGpPWpGaD
Tretinoin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—muscle cancer	0.000107	0.00578	CbGpPWpGaD
Tretinoin—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000107	0.00575	CbGpPWpGaD
Tretinoin—CYP4A11—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000103	0.00554	CbGpPWpGaD
Tretinoin—CYP2C18—Tryptophan metabolism—MDM2—muscle cancer	9.96e-05	0.00537	CbGpPWpGaD
Tretinoin—RXRA—Adipogenesis—HMGA1—muscle cancer	9.9e-05	0.00534	CbGpPWpGaD
Tretinoin—RARG—Generic Transcription Pathway—MED12—muscle cancer	9.74e-05	0.00525	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—FH—muscle cancer	9.55e-05	0.00515	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—FH—muscle cancer	9.55e-05	0.00515	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—FH—muscle cancer	9.55e-05	0.00515	CbGpPWpGaD
Tretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	9.21e-05	0.00497	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	8.93e-05	0.00481	CbGpPWpGaD
Tretinoin—RXRG—Generic Transcription Pathway—MED12—muscle cancer	8.91e-05	0.0048	CbGpPWpGaD
Tretinoin—RARB—Generic Transcription Pathway—MED12—muscle cancer	8.73e-05	0.00471	CbGpPWpGaD
Tretinoin—RXRB—Generic Transcription Pathway—MED12—muscle cancer	8.37e-05	0.00451	CbGpPWpGaD
Tretinoin—RARA—Generic Transcription Pathway—MED12—muscle cancer	8.37e-05	0.00451	CbGpPWpGaD
Tretinoin—RXRA—Regulation of Androgen receptor activity—MDM2—muscle cancer	8.07e-05	0.00435	CbGpPWpGaD
Tretinoin—Chest pain—Etoposide—muscle cancer	7.77e-05	0.000998	CcSEcCtD
Tretinoin—Affect lability—Doxorubicin—muscle cancer	7.74e-05	0.000994	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	7.72e-05	0.000991	CcSEcCtD
Tretinoin—Pancreatitis—Methotrexate—muscle cancer	7.69e-05	0.000988	CcSEcCtD
Tretinoin—Discomfort—Etoposide—muscle cancer	7.68e-05	0.000986	CcSEcCtD
Tretinoin—Face oedema—Doxorubicin—muscle cancer	7.59e-05	0.000975	CcSEcCtD
Tretinoin—Hypersensitivity—Dactinomycin—muscle cancer	7.58e-05	0.000974	CcSEcCtD
Tretinoin—Abdominal discomfort—Methotrexate—muscle cancer	7.52e-05	0.000966	CcSEcCtD
Tretinoin—Gastrointestinal pain—Vincristine—muscle cancer	7.52e-05	0.000966	CcSEcCtD
Tretinoin—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	7.52e-05	0.00405	CbGpPWpGaD
Tretinoin—Confusional state—Etoposide—muscle cancer	7.51e-05	0.000965	CcSEcCtD
Tretinoin—Cardiac arrest—Doxorubicin—muscle cancer	7.47e-05	0.00096	CcSEcCtD
Tretinoin—Anaphylactic shock—Etoposide—muscle cancer	7.45e-05	0.000957	CcSEcCtD
Tretinoin—Mood swings—Doxorubicin—muscle cancer	7.45e-05	0.000956	CcSEcCtD
Tretinoin—Infection—Etoposide—muscle cancer	7.4e-05	0.000951	CcSEcCtD
Tretinoin—Asthenia—Dactinomycin—muscle cancer	7.38e-05	0.000948	CcSEcCtD
Tretinoin—Blood creatinine increased—Doxorubicin—muscle cancer	7.36e-05	0.000946	CcSEcCtD
Tretinoin—Neutropenia—Methotrexate—muscle cancer	7.34e-05	0.000942	CcSEcCtD
Tretinoin—Dysuria—Methotrexate—muscle cancer	7.34e-05	0.000942	CcSEcCtD
Tretinoin—Dehydration—Doxorubicin—muscle cancer	7.31e-05	0.000939	CcSEcCtD
Tretinoin—Thrombocytopenia—Etoposide—muscle cancer	7.29e-05	0.000937	CcSEcCtD
Tretinoin—Upper respiratory tract infection—Methotrexate—muscle cancer	7.29e-05	0.000937	CcSEcCtD
Tretinoin—RXRA—Developmental Biology—MYOG—muscle cancer	7.27e-05	0.00392	CbGpPWpGaD
Tretinoin—Tachycardia—Etoposide—muscle cancer	7.27e-05	0.000934	CcSEcCtD
Tretinoin—Abdominal pain—Vincristine—muscle cancer	7.27e-05	0.000934	CcSEcCtD
Tretinoin—Body temperature increased—Vincristine—muscle cancer	7.27e-05	0.000934	CcSEcCtD
Tretinoin—Skin disorder—Etoposide—muscle cancer	7.23e-05	0.000929	CcSEcCtD
Tretinoin—Dry skin—Doxorubicin—muscle cancer	7.2e-05	0.000925	CcSEcCtD
Tretinoin—Hyperhidrosis—Etoposide—muscle cancer	7.2e-05	0.000925	CcSEcCtD
Tretinoin—Photosensitivity reaction—Methotrexate—muscle cancer	7.16e-05	0.00092	CcSEcCtD
Tretinoin—Anorexia—Etoposide—muscle cancer	7.1e-05	0.000912	CcSEcCtD
Tretinoin—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	7.08e-05	0.000909	CcSEcCtD
Tretinoin—Diarrhoea—Dactinomycin—muscle cancer	7.04e-05	0.000905	CcSEcCtD
Tretinoin—Pneumonia—Methotrexate—muscle cancer	7.04e-05	0.000904	CcSEcCtD
Tretinoin—Nasopharyngitis—Doxorubicin—muscle cancer	7.03e-05	0.000903	CcSEcCtD
Tretinoin—Drowsiness—Methotrexate—muscle cancer	7e-05	0.000899	CcSEcCtD
Tretinoin—Infestation NOS—Methotrexate—muscle cancer	7e-05	0.000899	CcSEcCtD
Tretinoin—Infestation—Methotrexate—muscle cancer	7e-05	0.000899	CcSEcCtD
Tretinoin—Depression—Methotrexate—muscle cancer	6.98e-05	0.000896	CcSEcCtD
Tretinoin—Hypotension—Etoposide—muscle cancer	6.96e-05	0.000894	CcSEcCtD
Tretinoin—Gastritis—Doxorubicin—muscle cancer	6.96e-05	0.000894	CcSEcCtD
Tretinoin—Stevens-Johnson syndrome—Methotrexate—muscle cancer	6.94e-05	0.000891	CcSEcCtD
Tretinoin—Renal failure—Methotrexate—muscle cancer	6.88e-05	0.000883	CcSEcCtD
Tretinoin—Abdominal distension—Doxorubicin—muscle cancer	6.84e-05	0.000879	CcSEcCtD
Tretinoin—CYP1A1—PPARA activates gene expression—MED12—muscle cancer	6.83e-05	0.00368	CbGpPWpGaD
Tretinoin—Stomatitis—Methotrexate—muscle cancer	6.82e-05	0.000876	CcSEcCtD
Tretinoin—Conjunctivitis—Methotrexate—muscle cancer	6.8e-05	0.000873	CcSEcCtD
Tretinoin—Asthma—Doxorubicin—muscle cancer	6.79e-05	0.000873	CcSEcCtD
Tretinoin—Dysphagia—Doxorubicin—muscle cancer	6.79e-05	0.000873	CcSEcCtD
Tretinoin—Hypersensitivity—Vincristine—muscle cancer	6.77e-05	0.00087	CcSEcCtD
Tretinoin—Sweating—Methotrexate—muscle cancer	6.71e-05	0.000861	CcSEcCtD
Tretinoin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	6.69e-05	0.00361	CbGpPWpGaD
Tretinoin—Paraesthesia—Etoposide—muscle cancer	6.69e-05	0.000859	CcSEcCtD
Tretinoin—Haematuria—Methotrexate—muscle cancer	6.67e-05	0.000857	CcSEcCtD
Tretinoin—Pancreatitis—Doxorubicin—muscle cancer	6.66e-05	0.000856	CcSEcCtD
Tretinoin—Dyspnoea—Etoposide—muscle cancer	6.64e-05	0.000853	CcSEcCtD
Tretinoin—Somnolence—Etoposide—muscle cancer	6.62e-05	0.000851	CcSEcCtD
Tretinoin—Epistaxis—Methotrexate—muscle cancer	6.6e-05	0.000848	CcSEcCtD
Tretinoin—Asthenia—Vincristine—muscle cancer	6.6e-05	0.000847	CcSEcCtD
Tretinoin—RXRA—Adipogenesis—FOXO1—muscle cancer	6.56e-05	0.00354	CbGpPWpGaD
Tretinoin—Vomiting—Dactinomycin—muscle cancer	6.54e-05	0.000841	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	6.53e-05	0.00352	CbGpPWpGaD
Tretinoin—Agranulocytosis—Methotrexate—muscle cancer	6.53e-05	0.000839	CcSEcCtD
Tretinoin—Rash—Dactinomycin—muscle cancer	6.49e-05	0.000834	CcSEcCtD
Tretinoin—Decreased appetite—Etoposide—muscle cancer	6.47e-05	0.000832	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Etoposide—muscle cancer	6.43e-05	0.000826	CcSEcCtD
Tretinoin—Fatigue—Etoposide—muscle cancer	6.42e-05	0.000825	CcSEcCtD
Tretinoin—Constipation—Etoposide—muscle cancer	6.37e-05	0.000818	CcSEcCtD
Tretinoin—Pain—Etoposide—muscle cancer	6.37e-05	0.000818	CcSEcCtD
Tretinoin—Neutropenia—Doxorubicin—muscle cancer	6.35e-05	0.000816	CcSEcCtD
Tretinoin—Dysuria—Doxorubicin—muscle cancer	6.35e-05	0.000816	CcSEcCtD
Tretinoin—Upper respiratory tract infection—Doxorubicin—muscle cancer	6.31e-05	0.000811	CcSEcCtD
Tretinoin—Haemoglobin—Methotrexate—muscle cancer	6.31e-05	0.000811	CcSEcCtD
Tretinoin—Diarrhoea—Vincristine—muscle cancer	6.29e-05	0.000808	CcSEcCtD
Tretinoin—Hepatitis—Methotrexate—muscle cancer	6.28e-05	0.000807	CcSEcCtD
Tretinoin—Haemorrhage—Methotrexate—muscle cancer	6.28e-05	0.000807	CcSEcCtD
Tretinoin—Pollakiuria—Doxorubicin—muscle cancer	6.28e-05	0.000806	CcSEcCtD
Tretinoin—Pharyngitis—Methotrexate—muscle cancer	6.23e-05	0.000801	CcSEcCtD
Tretinoin—Urinary tract disorder—Methotrexate—muscle cancer	6.2e-05	0.000797	CcSEcCtD
Tretinoin—Photosensitivity reaction—Doxorubicin—muscle cancer	6.2e-05	0.000797	CcSEcCtD
Tretinoin—Weight increased—Doxorubicin—muscle cancer	6.18e-05	0.000794	CcSEcCtD
Tretinoin—Urethral disorder—Methotrexate—muscle cancer	6.16e-05	0.000791	CcSEcCtD
Tretinoin—Weight decreased—Doxorubicin—muscle cancer	6.15e-05	0.000789	CcSEcCtD
Tretinoin—Feeling abnormal—Etoposide—muscle cancer	6.14e-05	0.000788	CcSEcCtD
Tretinoin—Nausea—Dactinomycin—muscle cancer	6.11e-05	0.000785	CcSEcCtD
Tretinoin—Pneumonia—Doxorubicin—muscle cancer	6.09e-05	0.000783	CcSEcCtD
Tretinoin—Gastrointestinal pain—Etoposide—muscle cancer	6.09e-05	0.000782	CcSEcCtD
Tretinoin—Dizziness—Vincristine—muscle cancer	6.08e-05	0.000781	CcSEcCtD
Tretinoin—Infestation—Doxorubicin—muscle cancer	6.06e-05	0.000778	CcSEcCtD
Tretinoin—Drowsiness—Doxorubicin—muscle cancer	6.06e-05	0.000778	CcSEcCtD
Tretinoin—Infestation NOS—Doxorubicin—muscle cancer	6.06e-05	0.000778	CcSEcCtD
Tretinoin—Visual impairment—Methotrexate—muscle cancer	6.05e-05	0.000777	CcSEcCtD
Tretinoin—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	6.01e-05	0.000771	CcSEcCtD
Tretinoin—Renal failure—Doxorubicin—muscle cancer	5.95e-05	0.000765	CcSEcCtD
Tretinoin—Erythema multiforme—Methotrexate—muscle cancer	5.94e-05	0.000763	CcSEcCtD
Tretinoin—Neuropathy peripheral—Doxorubicin—muscle cancer	5.94e-05	0.000763	CcSEcCtD
Tretinoin—Urticaria—Etoposide—muscle cancer	5.92e-05	0.00076	CcSEcCtD
Tretinoin—Stomatitis—Doxorubicin—muscle cancer	5.9e-05	0.000758	CcSEcCtD
Tretinoin—Abdominal pain—Etoposide—muscle cancer	5.89e-05	0.000756	CcSEcCtD
Tretinoin—Body temperature increased—Etoposide—muscle cancer	5.89e-05	0.000756	CcSEcCtD
Tretinoin—Conjunctivitis—Doxorubicin—muscle cancer	5.89e-05	0.000756	CcSEcCtD
Tretinoin—Urinary tract infection—Doxorubicin—muscle cancer	5.89e-05	0.000756	CcSEcCtD
Tretinoin—Eye disorder—Methotrexate—muscle cancer	5.87e-05	0.000754	CcSEcCtD
Tretinoin—Tinnitus—Methotrexate—muscle cancer	5.85e-05	0.000752	CcSEcCtD
Tretinoin—Vomiting—Vincristine—muscle cancer	5.85e-05	0.000751	CcSEcCtD
Tretinoin—NR0B1—Gene Expression—MED12—muscle cancer	5.82e-05	0.00314	CbGpPWpGaD
Tretinoin—Sweating—Doxorubicin—muscle cancer	5.81e-05	0.000746	CcSEcCtD
Tretinoin—Rash—Vincristine—muscle cancer	5.8e-05	0.000745	CcSEcCtD
Tretinoin—Dermatitis—Vincristine—muscle cancer	5.79e-05	0.000744	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.79e-05	0.00312	CbGpPWpGaD
Tretinoin—Haematuria—Doxorubicin—muscle cancer	5.78e-05	0.000742	CcSEcCtD
Tretinoin—Headache—Vincristine—muscle cancer	5.76e-05	0.00074	CcSEcCtD
Tretinoin—Epistaxis—Doxorubicin—muscle cancer	5.71e-05	0.000734	CcSEcCtD
Tretinoin—Angiopathy—Methotrexate—muscle cancer	5.7e-05	0.000732	CcSEcCtD
Tretinoin—Sinusitis—Doxorubicin—muscle cancer	5.68e-05	0.00073	CcSEcCtD
Tretinoin—Agranulocytosis—Doxorubicin—muscle cancer	5.65e-05	0.000726	CcSEcCtD
Tretinoin—Chills—Methotrexate—muscle cancer	5.63e-05	0.000724	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	5.58e-05	0.00301	CbGpPWpGaD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	5.55e-05	0.00299	CbGpPWpGaD
Tretinoin—Alopecia—Methotrexate—muscle cancer	5.55e-05	0.000713	CcSEcCtD
Tretinoin—Mental disorder—Methotrexate—muscle cancer	5.5e-05	0.000707	CcSEcCtD
Tretinoin—Hypersensitivity—Etoposide—muscle cancer	5.49e-05	0.000705	CcSEcCtD
Tretinoin—Malnutrition—Methotrexate—muscle cancer	5.47e-05	0.000702	CcSEcCtD
Tretinoin—Erythema—Methotrexate—muscle cancer	5.47e-05	0.000702	CcSEcCtD
Tretinoin—Haemoglobin—Doxorubicin—muscle cancer	5.47e-05	0.000702	CcSEcCtD
Tretinoin—Nausea—Vincristine—muscle cancer	5.46e-05	0.000702	CcSEcCtD
Tretinoin—Hepatitis—Doxorubicin—muscle cancer	5.44e-05	0.000698	CcSEcCtD
Tretinoin—Haemorrhage—Doxorubicin—muscle cancer	5.44e-05	0.000698	CcSEcCtD
Tretinoin—Hypoaesthesia—Doxorubicin—muscle cancer	5.41e-05	0.000695	CcSEcCtD
Tretinoin—ALDH1A1—Metabolism—MED12—muscle cancer	5.4e-05	0.00291	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—MED12—muscle cancer	5.4e-05	0.00291	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—MED12—muscle cancer	5.4e-05	0.00291	CbGpPWpGaD
Tretinoin—Pharyngitis—Doxorubicin—muscle cancer	5.4e-05	0.000693	CcSEcCtD
Tretinoin—Urinary tract disorder—Doxorubicin—muscle cancer	5.37e-05	0.00069	CcSEcCtD
Tretinoin—Oedema peripheral—Doxorubicin—muscle cancer	5.36e-05	0.000688	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	5.35e-05	0.00289	CbGpPWpGaD
Tretinoin—Asthenia—Etoposide—muscle cancer	5.34e-05	0.000686	CcSEcCtD
Tretinoin—Urethral disorder—Doxorubicin—muscle cancer	5.33e-05	0.000685	CcSEcCtD
Tretinoin—Back pain—Methotrexate—muscle cancer	5.29e-05	0.000679	CcSEcCtD
Tretinoin—Pruritus—Etoposide—muscle cancer	5.27e-05	0.000677	CcSEcCtD
Tretinoin—Visual impairment—Doxorubicin—muscle cancer	5.24e-05	0.000673	CcSEcCtD
Tretinoin—Vision blurred—Methotrexate—muscle cancer	5.15e-05	0.000662	CcSEcCtD
Tretinoin—Erythema multiforme—Doxorubicin—muscle cancer	5.14e-05	0.00066	CcSEcCtD
Tretinoin—Diarrhoea—Etoposide—muscle cancer	5.1e-05	0.000655	CcSEcCtD
Tretinoin—Eye disorder—Doxorubicin—muscle cancer	5.08e-05	0.000653	CcSEcCtD
Tretinoin—Ill-defined disorder—Methotrexate—muscle cancer	5.07e-05	0.000652	CcSEcCtD
Tretinoin—Tinnitus—Doxorubicin—muscle cancer	5.07e-05	0.000651	CcSEcCtD
Tretinoin—Anaemia—Methotrexate—muscle cancer	5.05e-05	0.000649	CcSEcCtD
Tretinoin—Flushing—Doxorubicin—muscle cancer	5.05e-05	0.000648	CcSEcCtD
Tretinoin—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	4.96e-05	0.00267	CbGpPWpGaD
Tretinoin—Angiopathy—Doxorubicin—muscle cancer	4.93e-05	0.000634	CcSEcCtD
Tretinoin—Malaise—Methotrexate—muscle cancer	4.93e-05	0.000633	CcSEcCtD
Tretinoin—Dizziness—Etoposide—muscle cancer	4.93e-05	0.000633	CcSEcCtD
Tretinoin—CRABP2—Metabolism—ENO2—muscle cancer	4.92e-05	0.00265	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—ENO2—muscle cancer	4.92e-05	0.00265	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—ENO2—muscle cancer	4.92e-05	0.00265	CbGpPWpGaD
Tretinoin—Chills—Doxorubicin—muscle cancer	4.88e-05	0.000627	CcSEcCtD
Tretinoin—Arrhythmia—Doxorubicin—muscle cancer	4.86e-05	0.000624	CcSEcCtD
Tretinoin—Alopecia—Doxorubicin—muscle cancer	4.81e-05	0.000617	CcSEcCtD
Tretinoin—Cough—Methotrexate—muscle cancer	4.77e-05	0.000613	CcSEcCtD
Tretinoin—Mental disorder—Doxorubicin—muscle cancer	4.76e-05	0.000612	CcSEcCtD
Tretinoin—Convulsion—Methotrexate—muscle cancer	4.74e-05	0.000608	CcSEcCtD
Tretinoin—Vomiting—Etoposide—muscle cancer	4.74e-05	0.000608	CcSEcCtD
Tretinoin—Erythema—Doxorubicin—muscle cancer	4.73e-05	0.000608	CcSEcCtD
Tretinoin—Malnutrition—Doxorubicin—muscle cancer	4.73e-05	0.000608	CcSEcCtD
Tretinoin—Rash—Etoposide—muscle cancer	4.7e-05	0.000603	CcSEcCtD
Tretinoin—Dermatitis—Etoposide—muscle cancer	4.69e-05	0.000603	CcSEcCtD
Tretinoin—RARG—Gene Expression—MED12—muscle cancer	4.69e-05	0.00253	CbGpPWpGaD
Tretinoin—Headache—Etoposide—muscle cancer	4.67e-05	0.000599	CcSEcCtD
Tretinoin—Flatulence—Doxorubicin—muscle cancer	4.66e-05	0.000599	CcSEcCtD
Tretinoin—Chest pain—Methotrexate—muscle cancer	4.65e-05	0.000598	CcSEcCtD
Tretinoin—Myalgia—Methotrexate—muscle cancer	4.65e-05	0.000598	CcSEcCtD
Tretinoin—Arthralgia—Methotrexate—muscle cancer	4.65e-05	0.000598	CcSEcCtD
Tretinoin—Tension—Doxorubicin—muscle cancer	4.64e-05	0.000597	CcSEcCtD
Tretinoin—CYP4A11—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.63e-05	0.00249	CbGpPWpGaD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	4.62e-05	0.000594	CcSEcCtD
Tretinoin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	4.61e-05	0.00248	CbGpPWpGaD
Tretinoin—Discomfort—Methotrexate—muscle cancer	4.6e-05	0.000591	CcSEcCtD
Tretinoin—Nervousness—Doxorubicin—muscle cancer	4.6e-05	0.000591	CcSEcCtD
Tretinoin—Back pain—Doxorubicin—muscle cancer	4.58e-05	0.000588	CcSEcCtD
Tretinoin—CYP2A6—Fluoropyrimidine Activity—TP53—muscle cancer	4.54e-05	0.00245	CbGpPWpGaD
Tretinoin—CYP1A1—Tryptophan metabolism—MDM2—muscle cancer	4.52e-05	0.00244	CbGpPWpGaD
Tretinoin—Confusional state—Methotrexate—muscle cancer	4.5e-05	0.000578	CcSEcCtD
Tretinoin—RXRA—Developmental Biology—MYOD1—muscle cancer	4.49e-05	0.00242	CbGpPWpGaD
Tretinoin—Anaphylactic shock—Methotrexate—muscle cancer	4.46e-05	0.000573	CcSEcCtD
Tretinoin—Vision blurred—Doxorubicin—muscle cancer	4.46e-05	0.000573	CcSEcCtD
Tretinoin—Infection—Methotrexate—muscle cancer	4.43e-05	0.000569	CcSEcCtD
Tretinoin—Nausea—Etoposide—muscle cancer	4.42e-05	0.000568	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.4e-05	0.00237	CbGpPWpGaD
Tretinoin—Ill-defined disorder—Doxorubicin—muscle cancer	4.39e-05	0.000564	CcSEcCtD
Tretinoin—Nervous system disorder—Methotrexate—muscle cancer	4.38e-05	0.000562	CcSEcCtD
Tretinoin—Anaemia—Doxorubicin—muscle cancer	4.38e-05	0.000562	CcSEcCtD
Tretinoin—Thrombocytopenia—Methotrexate—muscle cancer	4.37e-05	0.000561	CcSEcCtD
Tretinoin—RXRA—Generic Transcription Pathway—MED12—muscle cancer	4.36e-05	0.00235	CbGpPWpGaD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	4.36e-05	0.00235	CbGpPWpGaD
Tretinoin—Agitation—Doxorubicin—muscle cancer	4.35e-05	0.000559	CcSEcCtD
Tretinoin—Skin disorder—Methotrexate—muscle cancer	4.33e-05	0.000557	CcSEcCtD
Tretinoin—Hyperhidrosis—Methotrexate—muscle cancer	4.31e-05	0.000554	CcSEcCtD
Tretinoin—RXRG—Gene Expression—MED12—muscle cancer	4.29e-05	0.00231	CbGpPWpGaD
Tretinoin—Malaise—Doxorubicin—muscle cancer	4.27e-05	0.000548	CcSEcCtD
Tretinoin—Anorexia—Methotrexate—muscle cancer	4.25e-05	0.000546	CcSEcCtD
Tretinoin—Syncope—Doxorubicin—muscle cancer	4.24e-05	0.000545	CcSEcCtD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	4.22e-05	0.00227	CbGpPWpGaD
Tretinoin—RARB—Gene Expression—MED12—muscle cancer	4.21e-05	0.00227	CbGpPWpGaD
Tretinoin—Palpitations—Doxorubicin—muscle cancer	4.18e-05	0.000537	CcSEcCtD
Tretinoin—Hypotension—Methotrexate—muscle cancer	4.17e-05	0.000536	CcSEcCtD
Tretinoin—Loss of consciousness—Doxorubicin—muscle cancer	4.16e-05	0.000534	CcSEcCtD
Tretinoin—Cough—Doxorubicin—muscle cancer	4.13e-05	0.000531	CcSEcCtD
Tretinoin—RXRA—Developmental Biology—MED12—muscle cancer	4.11e-05	0.00221	CbGpPWpGaD
Tretinoin—Convulsion—Doxorubicin—muscle cancer	4.1e-05	0.000527	CcSEcCtD
Tretinoin—Hypertension—Doxorubicin—muscle cancer	4.09e-05	0.000525	CcSEcCtD
Tretinoin—CYP1A1—Arachidonic acid metabolism—PTGS2—muscle cancer	4.08e-05	0.0022	CbGpPWpGaD
Tretinoin—Musculoskeletal discomfort—Methotrexate—muscle cancer	4.06e-05	0.000522	CcSEcCtD
Tretinoin—Insomnia—Methotrexate—muscle cancer	4.04e-05	0.000518	CcSEcCtD
Tretinoin—RXRB—Gene Expression—MED12—muscle cancer	4.03e-05	0.00217	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—MED12—muscle cancer	4.03e-05	0.00217	CbGpPWpGaD
Tretinoin—Arthralgia—Doxorubicin—muscle cancer	4.03e-05	0.000518	CcSEcCtD
Tretinoin—Myalgia—Doxorubicin—muscle cancer	4.03e-05	0.000518	CcSEcCtD
Tretinoin—Chest pain—Doxorubicin—muscle cancer	4.03e-05	0.000518	CcSEcCtD
Tretinoin—Anxiety—Doxorubicin—muscle cancer	4.02e-05	0.000516	CcSEcCtD
Tretinoin—Paraesthesia—Methotrexate—muscle cancer	4.01e-05	0.000515	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	4e-05	0.000514	CcSEcCtD
Tretinoin—Discomfort—Doxorubicin—muscle cancer	3.98e-05	0.000511	CcSEcCtD
Tretinoin—Dyspnoea—Methotrexate—muscle cancer	3.98e-05	0.000511	CcSEcCtD
Tretinoin—Somnolence—Methotrexate—muscle cancer	3.97e-05	0.000509	CcSEcCtD
Tretinoin—Dry mouth—Doxorubicin—muscle cancer	3.94e-05	0.000506	CcSEcCtD
Tretinoin—Dyspepsia—Methotrexate—muscle cancer	3.93e-05	0.000504	CcSEcCtD
Tretinoin—Confusional state—Doxorubicin—muscle cancer	3.9e-05	0.0005	CcSEcCtD
Tretinoin—Decreased appetite—Methotrexate—muscle cancer	3.88e-05	0.000498	CcSEcCtD
Tretinoin—Anaphylactic shock—Doxorubicin—muscle cancer	3.86e-05	0.000496	CcSEcCtD
Tretinoin—Oedema—Doxorubicin—muscle cancer	3.86e-05	0.000496	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Methotrexate—muscle cancer	3.85e-05	0.000495	CcSEcCtD
Tretinoin—CRABP1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.85e-05	0.00207	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.85e-05	0.00207	CbGpPWpGaD
Tretinoin—Fatigue—Methotrexate—muscle cancer	3.85e-05	0.000494	CcSEcCtD
Tretinoin—Infection—Doxorubicin—muscle cancer	3.84e-05	0.000493	CcSEcCtD
Tretinoin—Pain—Methotrexate—muscle cancer	3.82e-05	0.00049	CcSEcCtD
Tretinoin—Shock—Doxorubicin—muscle cancer	3.8e-05	0.000488	CcSEcCtD
Tretinoin—Nervous system disorder—Doxorubicin—muscle cancer	3.79e-05	0.000487	CcSEcCtD
Tretinoin—Thrombocytopenia—Doxorubicin—muscle cancer	3.78e-05	0.000486	CcSEcCtD
Tretinoin—Tachycardia—Doxorubicin—muscle cancer	3.77e-05	0.000484	CcSEcCtD
Tretinoin—Skin disorder—Doxorubicin—muscle cancer	3.75e-05	0.000482	CcSEcCtD
Tretinoin—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	3.74e-05	0.00202	CbGpPWpGaD
Tretinoin—Hyperhidrosis—Doxorubicin—muscle cancer	3.73e-05	0.00048	CcSEcCtD
Tretinoin—Anorexia—Doxorubicin—muscle cancer	3.68e-05	0.000473	CcSEcCtD
Tretinoin—Feeling abnormal—Methotrexate—muscle cancer	3.68e-05	0.000472	CcSEcCtD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.67e-05	0.00198	CbGpPWpGaD
Tretinoin—Gastrointestinal pain—Methotrexate—muscle cancer	3.65e-05	0.000469	CcSEcCtD
Tretinoin—CYP4A11—Metabolism—FH—muscle cancer	3.65e-05	0.00197	CbGpPWpGaD
Tretinoin—Hypotension—Doxorubicin—muscle cancer	3.61e-05	0.000464	CcSEcCtD
Tretinoin—Urticaria—Methotrexate—muscle cancer	3.54e-05	0.000455	CcSEcCtD
Tretinoin—Abdominal pain—Methotrexate—muscle cancer	3.53e-05	0.000453	CcSEcCtD
Tretinoin—Body temperature increased—Methotrexate—muscle cancer	3.53e-05	0.000453	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Doxorubicin—muscle cancer	3.52e-05	0.000452	CcSEcCtD
Tretinoin—Insomnia—Doxorubicin—muscle cancer	3.49e-05	0.000449	CcSEcCtD
Tretinoin—Paraesthesia—Doxorubicin—muscle cancer	3.47e-05	0.000446	CcSEcCtD
Tretinoin—Dyspnoea—Doxorubicin—muscle cancer	3.44e-05	0.000442	CcSEcCtD
Tretinoin—Somnolence—Doxorubicin—muscle cancer	3.43e-05	0.000441	CcSEcCtD
Tretinoin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	3.43e-05	0.00185	CbGpPWpGaD
Tretinoin—Dyspepsia—Doxorubicin—muscle cancer	3.4e-05	0.000437	CcSEcCtD
Tretinoin—Decreased appetite—Doxorubicin—muscle cancer	3.36e-05	0.000431	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Doxorubicin—muscle cancer	3.34e-05	0.000428	CcSEcCtD
Tretinoin—Fatigue—Doxorubicin—muscle cancer	3.33e-05	0.000428	CcSEcCtD
Tretinoin—RARB—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.32e-05	0.00179	CbGpPWpGaD
Tretinoin—Constipation—Doxorubicin—muscle cancer	3.3e-05	0.000424	CcSEcCtD
Tretinoin—Pain—Doxorubicin—muscle cancer	3.3e-05	0.000424	CcSEcCtD
Tretinoin—Hypersensitivity—Methotrexate—muscle cancer	3.29e-05	0.000422	CcSEcCtD
Tretinoin—Asthenia—Methotrexate—muscle cancer	3.2e-05	0.000411	CcSEcCtD
Tretinoin—CYP2C18—Metabolism—FH—muscle cancer	3.19e-05	0.00172	CbGpPWpGaD
Tretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.19e-05	0.00172	CbGpPWpGaD
Tretinoin—Feeling abnormal—Doxorubicin—muscle cancer	3.18e-05	0.000409	CcSEcCtD
Tretinoin—Gastrointestinal pain—Doxorubicin—muscle cancer	3.16e-05	0.000406	CcSEcCtD
Tretinoin—Pruritus—Methotrexate—muscle cancer	3.16e-05	0.000405	CcSEcCtD
Tretinoin—Urticaria—Doxorubicin—muscle cancer	3.07e-05	0.000394	CcSEcCtD
Tretinoin—Body temperature increased—Doxorubicin—muscle cancer	3.05e-05	0.000392	CcSEcCtD
Tretinoin—Abdominal pain—Doxorubicin—muscle cancer	3.05e-05	0.000392	CcSEcCtD
Tretinoin—Diarrhoea—Methotrexate—muscle cancer	3.05e-05	0.000392	CcSEcCtD
Tretinoin—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	3.04e-05	0.00164	CbGpPWpGaD
Tretinoin—Dizziness—Methotrexate—muscle cancer	2.95e-05	0.000379	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	2.89e-05	0.00156	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—FH—muscle cancer	2.89e-05	0.00156	CbGpPWpGaD
Tretinoin—Hypersensitivity—Doxorubicin—muscle cancer	2.85e-05	0.000366	CcSEcCtD
Tretinoin—Vomiting—Methotrexate—muscle cancer	2.84e-05	0.000364	CcSEcCtD
Tretinoin—Rash—Methotrexate—muscle cancer	2.81e-05	0.000361	CcSEcCtD
Tretinoin—Dermatitis—Methotrexate—muscle cancer	2.81e-05	0.000361	CcSEcCtD
Tretinoin—Headache—Methotrexate—muscle cancer	2.79e-05	0.000359	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	2.79e-05	0.0015	CbGpPWpGaD
Tretinoin—Asthenia—Doxorubicin—muscle cancer	2.77e-05	0.000356	CcSEcCtD
Tretinoin—Pruritus—Doxorubicin—muscle cancer	2.73e-05	0.000351	CcSEcCtD
Tretinoin—Nausea—Methotrexate—muscle cancer	2.65e-05	0.00034	CcSEcCtD
Tretinoin—Diarrhoea—Doxorubicin—muscle cancer	2.64e-05	0.00034	CcSEcCtD
Tretinoin—Dizziness—Doxorubicin—muscle cancer	2.55e-05	0.000328	CcSEcCtD
Tretinoin—Vomiting—Doxorubicin—muscle cancer	2.46e-05	0.000316	CcSEcCtD
Tretinoin—Rash—Doxorubicin—muscle cancer	2.44e-05	0.000313	CcSEcCtD
Tretinoin—Dermatitis—Doxorubicin—muscle cancer	2.43e-05	0.000313	CcSEcCtD
Tretinoin—Headache—Doxorubicin—muscle cancer	2.42e-05	0.000311	CcSEcCtD
Tretinoin—Nausea—Doxorubicin—muscle cancer	2.29e-05	0.000295	CcSEcCtD
Tretinoin—RXRA—Developmental Biology—FOXO1—muscle cancer	2.25e-05	0.00122	CbGpPWpGaD
Tretinoin—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	2.23e-05	0.0012	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.2e-05	0.00118	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—FH—muscle cancer	2.12e-05	0.00114	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—MED12—muscle cancer	2.1e-05	0.00113	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—MED12—muscle cancer	2.06e-05	0.00111	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—FH—muscle cancer	1.94e-05	0.00105	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—ENO2—muscle cancer	1.88e-05	0.00101	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.84e-05	0.00099	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—MED12—muscle cancer	1.8e-05	0.000971	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—PTGS2—muscle cancer	1.71e-05	0.000924	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—PTGS2—muscle cancer	1.71e-05	0.000924	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—PTGS2—muscle cancer	1.71e-05	0.000924	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.68e-05	0.000907	CbGpPWpGaD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.66e-05	0.000895	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—ENO2—muscle cancer	1.64e-05	0.000885	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—MED12—muscle cancer	1.63e-05	0.000881	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—FH—muscle cancer	1.57e-05	0.000845	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—FH—muscle cancer	1.53e-05	0.000826	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—ENO2—muscle cancer	1.49e-05	0.000803	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.47e-05	0.000792	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—FH—muscle cancer	1.45e-05	0.00078	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.37e-05	0.000738	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—FH—muscle cancer	1.33e-05	0.000715	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—MED12—muscle cancer	1.2e-05	0.000645	CbGpPWpGaD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.16e-05	0.000628	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—MED12—muscle cancer	1.1e-05	0.000591	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—ENO2—muscle cancer	1.09e-05	0.000588	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—FH—muscle cancer	1.08e-05	0.000582	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—VEGFA—muscle cancer	1.03e-05	0.000554	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—ENO2—muscle cancer	1e-05	0.000539	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—MED12—muscle cancer	8.85e-06	0.000477	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—MED12—muscle cancer	8.65e-06	0.000466	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—MED12—muscle cancer	8.17e-06	0.000441	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—ENO2—muscle cancer	8.07e-06	0.000435	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—ENO2—muscle cancer	7.89e-06	0.000425	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—MED12—muscle cancer	7.49e-06	0.000404	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—ENO2—muscle cancer	7.45e-06	0.000402	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—FH—muscle cancer	7.12e-06	0.000384	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—ENO2—muscle cancer	6.83e-06	0.000368	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PTGS2—muscle cancer	6.54e-06	0.000353	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—MED12—muscle cancer	6.1e-06	0.000329	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.83e-06	0.000314	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PTGS2—muscle cancer	5.72e-06	0.000308	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—ENO2—muscle cancer	5.56e-06	0.0003	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.34e-06	0.000288	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PTGS2—muscle cancer	5.19e-06	0.00028	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.35e-06	0.000234	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—MED12—muscle cancer	4.02e-06	0.000217	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PTGS2—muscle cancer	3.8e-06	0.000205	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—ENO2—muscle cancer	3.67e-06	0.000198	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PTGS2—muscle cancer	3.48e-06	0.000188	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PTGS2—muscle cancer	2.81e-06	0.000152	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PTGS2—muscle cancer	2.75e-06	0.000148	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PTGS2—muscle cancer	2.6e-06	0.00014	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PTGS2—muscle cancer	2.38e-06	0.000128	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PTGS2—muscle cancer	1.94e-06	0.000104	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PTGS2—muscle cancer	1.28e-06	6.89e-05	CbGpPWpGaD
